Prakt. lékáren. 2022; 18(4): 27-36 [Klin Farmakol Farm. 2022;36(1):29-33]

Physico-chemical properties of colistin and their impact on clinical practice

Jitka Rychlíčková1, 2, Vendula Kubíčková3
1 Farmakologický ústav, Lékařská fakulta, Masarykova univerzita, Brno
2 International Clinical Research Center, Fakultní nemocnice u sv. Anny v Brně
3 Ústav farmakologie, Lékařská fakulta, Univerzita Palackého, Olomouc

Colistin, a lipopeptide antibacterial agent, has a narrow-spectrum bactericidal activity only against gram-negative bacteria. It is administered as an inactive prodrug - colistin methanesulphonate, which is spontaneously converted to the active colistin. Its stability is concentration-, temperature-, and pH-dependent; moreover, the type of the carrier solution also plays a role. The stability of the colistin prodrug solutions has several implications for clinical practice, whether in intravenous or inhalation administration. Appropriate storage and properly selected type of test tubes and laboratory equipment are essential in therapeutic drug monitoring procedures. The aim of this paper is to emphasize several aspects for safe and effective colistin use and therapeutic monitoring.

Keywords: colistin, stability, nebulization, adsorption, LC-MS.

Published: December 15, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rychlíčková J, Kubíčková V. Physico-chemical properties of colistin and their impact on clinical practice. Praktické lékárenství. 2022;18(4):27-36.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2006;50(6):1953-1958. Go to original source... Go to PubMed...
    2. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and prevalence of resistance. Curr Med Res Opin. 2015;31(4):707-721. Go to original source... Go to PubMed...
    3. Warren HS, Kania SA, Siber GR. Binding and neutralization of bacterial lipopolysaccharide by colistin nonapeptide. Antimicrob Agents Chemother. 1985;28(1):107-112. Go to original source... Go to PubMed...
    4. Velkov T, Thompson PE, Nation RL, Li J. Structure--activity relationships of polymyxin antibiotics. J Med Chem. 2010;53(5):1898-1916. Go to original source... Go to PubMed...
    5. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. Rapid killing of Acinetobacter baumannii by polymyxins is mediated by a hydroxyl radical death pathway. Antimicrob Agents Chemother. 2012;56(11):5642-5649. Go to original source... Go to PubMed...
    6. Ehrentraut SF, Muenster S, Kreyer S et al. Extensive Therapeutic Drug Monitoring of Colistin in Critically Ill Patients Reveals Undetected Risks. Microorganisms. 2020;8(3):415. Go to original source... Go to PubMed...
    7. Westerman EM, Le Brun PP, Touw DJ, Frijlink HW, Heijerman HG. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros. 2004;3(1):23-28. Go to original source... Go to PubMed...
    8. McCoy KS. Compounded colistimethate as possible cause of fatal acute respiratory distress syndrome. N Engl J Med. 2007;357(22):2310-2311. Go to original source... Go to PubMed...
    9. Abdellatif S, Trifi A, Daly F, Mahjoub K, Nasri R, Ben Lakhal S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016;6(1):26. Go to original source... Go to PubMed...
    10. Lu Q, Luo R, Bodin L et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012;117(6):1335-1347. Go to original source... Go to PubMed...
    11. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother. 2008;52(9):3047-3051. Go to original source... Go to PubMed...
    12. Healan AM, Gray W, Fuchs EJ, Griffiss JM, Salata RA, Blumer J. Stability of colistimethate sodium in aqueous solution. Anti­microb Agents Chemother. 2012;56(12):6432-6433. Go to original source... Go to PubMed...
    13. Bihan K, Zahr N, Becquemin MH et al. Influence of diluent volume of colistimethate sodium on aerosol characteristics and pharmacokinetics in ventilator-associated pneu­monia caused by MDR bacteria. J Antimicrob Chemother. 2018;73(6):1639-1646. Go to original source... Go to PubMed...
    14. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax. 1997;52(7):656-658. Go to original source... Go to PubMed...
    15. Schoeffel RE, Anderson SD, Altounyan RE. Bronchial hyperreactivity in response to inhalation of ultrasonically nebulised solutions of distilled water and saline. Br Med J (Clin Res Ed). 1981;283(6302):1285-1287. Go to original source... Go to PubMed...
    16. Boisson M, Jacobs M, Grégoire N et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014;58(12):7331-7339. Go to original source... Go to PubMed...
    17. Tsuji BT, Pogue JM, Zavascki AP et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39(1):10-39. Go to original source... Go to PubMed...
    18. Colomycin. Souhrn údajů o přípravku. Státní ústav pro kontrolu léčiv [online]. [cit. 2022-01-19]. Dostupné z: https://www.sukl.cz.
    19. Abdulla A, van Leeuwen RWF, de Vries Schultink AHM. Stability of colistimethate sodium in a disposable elastomeric infusion device. Int J Pharm. 2015;486:367-369. Go to original source... Go to PubMed...
    20. Post TE, Kamerling IMC, van Rossen RCJM et al. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. European Journal of Hospital Pharmacy. 2018;25:337-339. Go to original source... Go to PubMed...
    21. Michalopoulos A, Kasiakou SK, Rosmarakis ES, Falagas ME. Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin. Scand J Infect Dis. 2005;37(2):142-145. Go to original source...
    22. Kassamali Z, Curello J, Gregson A. Comparison of continuous versus intermittent intravenous infusion of colistimethate sodium (colistin) for treatment of carbapenem-resistant gram negative bacterial infections. 26th European Congress of Clinical Microbiology and Infectious Diseases. 2012, April 9-12. Amsterdam, Netherlands.
    23. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009;53(8):3430-3436. Go to original source... Go to PubMed...
    24. Mohamed AF, Karaiskos I, Plachouras D et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56(8):4241-4249. Go to original source... Go to PubMed...
    25. Markou N, Markantonis SL, Dimitrakis E et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study. Clin Ther. 2008;30(1):143-151. Go to original source... Go to PubMed...
    26. Menna P, Salvatorelli E, Mattei A, Cappiello D, Minotti G, Carassiti M. Modified Colistin Regimen for Critically Ill Patients with Acute Renal Impairment and Continuous Renal Replacement Therapy. Chemotherapy. 2018;63(1):35-38. Go to original source... Go to PubMed...
    27. Dudhani RV, Nation RL, Li J. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J Antimicrob Chemother. 2010;65(7):1412-1415. Go to original source... Go to PubMed...
    28. Gobin P, Lemaître F, Marchand S, Couet W, Olivier JC. Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother. 2010;54(5):1941-1948. Go to original source... Go to PubMed...
    29. Hanai Y, Matsuo K, Kosugi T et al. Rapid, simple, and clinically applicable high-performance liquid chromatography method for clinical determination of plasma colistin concentrations. J Pharm Health Care Sci. 2018;4(22). Go to original source... Go to PubMed...
    30. Binhashim NH, Alvi SN, Hammami MM. LC-MS/MS Method for Determination of Colistin in Human Plasma: Validation and Stability Studies. International Journal of Analytical Mass Spectrometry and Chromatography. 2021;9(1). Go to original source...
    31. Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O. Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions. Antimicrob Agents Chemother. 2017;61(11):e00857-17. Go to original source... Go to PubMed...
    32. Dagla I, Karkoula E, Baira E, Tsarbopoulos A, Gikas E. Analytical methodologies used for the determination of colistin in biological fluids. Is it still a challenge? J Pharmaceut Biomed. 2019;164:777-788. Go to original source... Go to PubMed...
    33. Zabidi MS, Abu Bakar R, Musa N, Wan Yusuf WN. Analytical methodologies for measuring colistin levels in pharmacokinetic studies. J Liq Chromatogr Relat. 2020;43:671-686. Go to original source...
    34. Qi B, Gijsen M, Van Brantegem P, De Vocht T, Deferm N, Abza GB, Nauwelaerts N, Wauters J, Spriet I, Annaert P. Quantitative determination of colistin A/B and colistin methanesulfonate in biological samples using hydrophilic interaction chromatography tandem mass spectrometry. Drug Test Anal. 2020;12:1183-1195. Go to original source... Go to PubMed...
    35. Leporati M, Bua RO, Mariano F, Carignano P, Stella M, Biancone L, Vincenti M. Determination by LC-MS/MS of Colistins A and B in Plasma and Ultrafiltrate From Critically Ill Patients Undergoing Continuous Venovenous Hemodiafiltration. Ther Drug Monit. 2014;36(2):182-191. Go to original source... Go to PubMed...
    36. Yuan H, Yu S, Chai G, Liu J, Zhou Q (Tony). A LC-MS/MS method for simultaneous analysis of the cystic fibrosis therapeutic drugs colistin, ivacaftor and ciprofloxacin. J Pharm Anal. 2021;11(6):732-738. Go to original source... Go to PubMed...
    37. Peng C, Zuo S, Qiu Y, Fu S, Peng L. Determination of Colistin in Contents Derived from Gastrointestinal Tract of Feeding Treated Piglet and Broiler. Antibiotics. 2021;10(4):422. Go to original source... Go to PubMed...
    38. Binhashim NH, Alvi SN, Hammami MM. LC-MS/MS Method for Determination of Colistin in Human Plasma: Validation and Stability Studies. Int J Anal Mass Spectrom Chromatogr. 2021;9:1-11. Go to original source...
    39. Zhao M, Wu X-J, Fan Y-X, Guo B-N, Zhang J. Development and validation of a UHPLC-MS/MS assay for colistin methane­sulphonate (CMS) and colistin in human plasma and urine using weak-cation exchange solid-phase extraction. J Pharmaceut Biomed. 2016;124:303-308. Go to original source... Go to PubMed...
    40. Cangemi G, Barco S, Castagnola E, Tripodi G, Favata F, D'Avolio A. Development and validation of UHPLC-MS/MS methods for the quantification of colistin in plasma and dried plasma spots. J Pharmaceut Biomed. 2016;129:551-557. Go to original source... Go to PubMed...
    41. Bihan K, Lu Q, Enjalbert M, Apparuit M, Langeron O, Rouby J-J, Funck-Brentano C, Zahr N. Determination of Colistin and Colistimethate Levels in Human Plasma and Urine by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Ther Drug Monit. 2016;38(6):796-803. Go to original source... Go to PubMed...
    42. Gaugain M, Raynaud A, Bourcier S, Verdon E, Hurtaud-Pessel D. Development of a liquid chromatography-tandem mass spectrometry method to determine colistin, bacitracin and virginiamycin M1 at cross-contamination levels in animal feed. Food Addit Contam A. 2021;38(9):1481-1494. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.